Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tranexamic acid + sucralfate is an investigational combination of two small-molecule drugs administered as a topical powder spray via endoscopy for the treatment of gastrointestinal bleeding. Developed by National Cheng Kung University Hospital, the combination leverages the antifibrinolytic properties of tranexamic acid, which inhibits fibrin degradation by binding to tissue plasminogen, and the mucosal protective properties of sucralfate, which forms a physical barrier over wound surfaces. This dual-action approach is intended to stabilize blood clots and protect the bleeding site from further irritation or degradation. Clinical evidence from pilot studies indicates that the combination significantly reduces rebleeding rates in patients with lower gastrointestinal bleeding when applied following standard endoscopic hemostasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tranexamic acid + sucralfate.